Olive Oil
ApprovedSmall molecule
AstraZenecaOlive Oil is one of 72 small molecule programs targeting Radiodermatitis. It is currently in Approved.
3
Indications
9
Total Trials
1
Active Trials
71
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
185 competitors in Irritable Bowel Syndrome
#DrugCompanyPhaseTrials
1Lialda
TakedaPhase 3
Xifaxan
SSalix
Phase 3
Zofran
NovartisPhase 3
Amitiza
SSucampo Pharma Americas, LLC
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Zarontin
PParkedale
Phase 3
Mesalazine
FerringPhase 3
Olive Oil
AstraZenecaApproved
Saccharomyces Boulardii
BBiocodex
Phase 3
Trulance
SSalix
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Irritable Bowel Syndrome1 trial
Dry Eye1 trial
Dry Eye Assessment and Management: Feasibility Study
Completed·—·Phase 2/3·NCT01102257·23 enrolled
2 more indications
Radiodermatitis1 trial
Use of Topical Olive Oil Cream for Prophylaxis Against Acute Radiodermatitis in Breast Cancer Patients
Completed·—·Phase 4·NCT05285943·132 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Olive Oil. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company